Chaturvedi S, Weispfenning A, Descamps T, Bellinvia S, Bauer D, Du R
Clin Transl Oncol. 2025; .
PMID: 39984775
DOI: 10.1007/s12094-025-03869-2.
Defty C, Krishna Y, Khan M, Sharma N, Tehrani H
Cureus. 2025; 17(1):e77583.
PMID: 39963638
PMC: 11830503.
DOI: 10.7759/cureus.77583.
Lolli G, Davini A, Tabanelli V, Sapienza M, Melle F, Motta G
EJHaem. 2025; 6(1):e1103.
PMID: 39927328
PMC: 11804214.
DOI: 10.1002/jha2.1103.
Di Maio D, Mitchell S, Batson S, Keeney E, Thom H
BMC Med Res Methodol. 2025; 25(1):30.
PMID: 39893424
PMC: 11786573.
DOI: 10.1186/s12874-025-02456-x.
Wang C, Dong Y, Men P, Zhang R, Xiao Y, Bu Y
Front Pharmacol. 2025; 15():1426772.
PMID: 39830356
PMC: 11738910.
DOI: 10.3389/fphar.2024.1426772.
Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma.
Zheng Z, Wang J, Sun R, Wang N, Weng X, Xu T
Signal Transduct Target Ther. 2025; 10(1):29.
PMID: 39828715
PMC: 11743790.
DOI: 10.1038/s41392-024-02105-7.
PET/CT-based target volume definition in involved-site radiotherapy for treatment of early-stage nodal follicular lymphoma.
Wark A, Kim J, Mavriopoulou E, Fougere C, Wiegel T, Scholz C
Strahlenther Onkol. 2025; .
PMID: 39808202
DOI: 10.1007/s00066-024-02356-x.
Safety in Subsequent Lines of Therapy in Patients With Relapsed/Refractory Follicular Lymphoma.
Bradley T, Davis M, Martin J, Woodward S
J Adv Pract Oncol. 2025; 1-16.
PMID: 39802526
PMC: 11715511.
DOI: 10.6004/jadpro.2024.15.8.21.
[Clinical characteristics and prognosis analysis in patients with bone marrow invasive follicular lymphoma].
Lyu R, Xiong W, Wang T, Yan Y, Wang Q, Yu Y
Zhonghua Xue Ye Xue Za Zhi. 2025; 45(12):1085-1090.
PMID: 39765348
PMC: 11886700.
DOI: 10.3760/cma.j.cn121090-20240613-00222.
Deauville Score-Based Evaluation of Interim PET/CT in Follicular Lymphoma: A Prognostic Factor Systematic Review and Meta-Analysis.
Fonseca J, Zloic S, Ayogu C, Marole K, Ingold G, Moreira S
Cureus. 2025; 16(12):e75169.
PMID: 39759650
PMC: 11699972.
DOI: 10.7759/cureus.75169.
Combining Total Metabolic Tumor Volume With Beta-2-Microglobulin Levels Predicts Outcomes in High-Burden Follicular Lymphoma Patients.
Zduniak A, Leveque E, Draye-Carbonnier S, Becker S, Tonnelet D, Dubois S
Hematol Oncol. 2024; 43(1):e70010.
PMID: 39676608
PMC: 11647558.
DOI: 10.1002/hon.70010.
The POD24 challenge: where do we go from here for early progressors?.
Mondello P, Casulo C
Hematology Am Soc Hematol Educ Program. 2024; 2024(1):301-309.
PMID: 39643981
PMC: 11665737.
DOI: 10.1182/hematology.2024000662.
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies.
Sehn L, Bartlett N, Matasar M, Schuster S, Assouline S, Giri P
Blood. 2024; 145(7):708-719.
PMID: 39447094
PMC: 11863491.
DOI: 10.1182/blood.2024025454.
Maximum disease diameter is associated with outcomes in stage II follicular lymphoma treated with radiation therapy alone.
Xu Y, Campbell B, Chan M, Chan J, Farinha P, Venner C
Clin Transl Radiat Oncol. 2024; 49:100869.
PMID: 39430799
PMC: 11488433.
DOI: 10.1016/j.ctro.2024.100869.
Targeting the Renin-angiotensin-aldosterone System (RAAS) for Cardiovascular Protection and Enhanced Oncological Outcomes: Review.
Pawlonka J, Buchalska B, Buczma K, Borzuta H, Kaminska K, Cudnoch-Jedrzejewska A
Curr Treat Options Oncol. 2024; 25(11):1406-1427.
PMID: 39422794
PMC: 11541340.
DOI: 10.1007/s11864-024-01270-9.
Is radiotherapy still the optimal initial choice for patients with early-stage low-grade follicular lymphoma in the modern era? A population-based study.
Zheng W, Wang S, Liang Y, Ning H
Ann Hematol. 2024; 103(11):4589-4598.
PMID: 39340635
PMC: 11534986.
DOI: 10.1007/s00277-024-06022-1.
A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma.
Li C, Bender B, Wilkins J, Li F, Turner D, Wang B
Clin Pharmacol Ther. 2024; 117(2):465-474.
PMID: 39328022
PMC: 11739751.
DOI: 10.1002/cpt.3445.
Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience.
Cassanello G, Drill E, Rivas-Delgado A, Okwali M, Isgor I, Caron P
Haematologica. 2024; 110(2):439-447.
PMID: 39234863
PMC: 11788635.
DOI: 10.3324/haematol.2024.285600.
Current and future therapies for follicular lymphoma.
Zinzani P, Munoz J, Trotman J
Exp Hematol Oncol. 2024; 13(1):87.
PMID: 39175100
PMC: 11340193.
DOI: 10.1186/s40164-024-00551-1.
Risk and impact of cytomegalovirus infection in lymphoma patients treated with bendamustine.
Huang J, Yeh C, Gong Y, Tsai M, Lin Y, Tsai C
Ann Hematol. 2024; 103(10):4099-4109.
PMID: 39158713
DOI: 10.1007/s00277-024-05839-0.
